Blood Pressure Medications Ranked: What Your Cardiologist Considers First

Cardiology · 6 · March 2, 2026

There are over 100 blood pressure medications available. Five major classes. Dozens of combinations. So when your doctor writes a prescription, it's not random. There's a decision tree based on your age, race, kidney function, diabetes status, and other conditions. Let's walk through how cardiologists actually rank these drugs.

First Line: ACE Inhibitors and ARBs

For most patients under 55 without other complications, ACE inhibitors (like lisinopril, enalapril, or ramipril) are the starting point. They block the renin-angiotensin system, relaxing blood vessels and reducing fluid retention. They're cheap, well-studied, and have decades of safety data. The HOPE trial showed ramipril reduced cardiovascular death by 26% in high-risk patients.

The main downside? A persistent dry cough affects about 10-15% of patients. It's annoying enough that many switch. That's where ARBs come in — losartan, valsartan, irbesartan. Same mechanism, different pathway, no cough. The LIFE trial demonstrated that losartan was superior to the beta-blocker atenolol for preventing stroke in hypertensive patients with left ventricular hypertrophy.

One critical note: never combine an ACE inhibitor with an ARB. The ONTARGET trial proved that dual blockade increases renal complications without improving outcomes. Pick one.

Second Line: Calcium Channel Blockers

Amlodipine is probably the most prescribed calcium channel blocker worldwide. It works by relaxing the smooth muscle in arterial walls, reducing peripheral resistance. It's particularly effective in older patients and Black patients, populations where the renin-angiotensin system is often less activated.

The ALLHAT trial — one of the largest hypertension studies ever conducted with over 33,000 patients — found amlodipine comparable to lisinopril and chlorthalidone for preventing major cardiovascular events. Ankle swelling is the most common side effect, affecting about 10% of patients at higher doses.

Third Line: Thiazide Diuretics

Chlorthalidone and hydrochlorothiazide are the workhorses here. They reduce blood volume by increasing sodium excretion in the kidneys. Cheap. Effective. Well-proven. The SPRINT trial used chlorthalidone as the backbone of its intensive blood pressure lowering protocol and showed a 25% reduction in major cardiovascular events when targeting systolic BP below 120 mmHg.

But thiazides aren't perfect. They can raise blood sugar slightly — a concern for pre-diabetic patients. They deplete potassium, requiring monitoring or supplementation. And they increase uric acid, which can trigger gout in susceptible individuals.

Fourth Line: Beta-Blockers

Here's where things get interesting. Beta-blockers (metoprolol, bisoprolol, carvedilol) used to be first-line therapy for hypertension. Not anymore. A 2024 meta-analysis in The Lancet confirmed what many cardiologists suspected: beta-blockers are inferior to other classes for preventing stroke in uncomplicated hypertension. They remain essential after a heart attack, in heart failure, and for rate control in atrial fibrillation. But for garden-variety high blood pressure? They've been demoted.

The Combination Reality

Most patients with significant hypertension need two or more drugs. And that's fine. A 2025 analysis in JAMA Cardiology found that starting with a low-dose combination pill (ACE inhibitor + calcium channel blocker, for example) achieved target blood pressure in 67% of patients, compared to 44% with single-drug therapy. The polypill approach is gaining traction globally, especially in resource-limited settings.

What About Newer Options?

Sacubitril/valsartan (Entresto) was originally approved for heart failure but is being studied in resistant hypertension. SGLT2 inhibitors like empagliflozin, primarily diabetes drugs, have shown modest blood pressure lowering alongside dramatic cardiovascular benefits. And renal denervation — a catheter-based procedure that disrupts nerve signals to the kidneys — showed promising results in the SPYRAL HTN-ON MED trial for patients who can't tolerate medications.

Key Takeaways

- ACE inhibitors or ARBs are first choice for most patients under 55 — never use both together

- Calcium channel blockers (amlodipine) are preferred in older adults and Black patients

- Beta-blockers are no longer first-line for uncomplicated hypertension but remain critical after heart attacks

- Most patients need two or more medications — low-dose combinations work better than maxing out a single drug

- Target blood pressure for most adults is below 130/80 mmHg per current ACC/AHA guidelines

Already on blood pressure medication? Track your readings and medication response over time with our wearable integration dashboard.